Roquefort Therapeutics plc

Equities

ROQ

GB00BMDQ2T15

Investment Management & Fund Operators

Delayed London S.E. Other stock markets 06:00:17 2024-04-29 am EDT			5-day change	1st Jan Change
4.54 ^GBX	-0.22%		-4.42%	-37.38%

Apr. 26	EARNINGS AND TRADING: Aura confident in Tiris; Cindrigo enters Germany	AN
Apr. 26	Earnings Flash (ROQ.L) ROQUEFORT THERAPEUTICS Reports FY23 Loss GBX-1.35	MT

Roquefort announces new sirNA sequences and patent filing

August 07, 2023 at 06:06 am EDT

Roquefort Therapeutics PLC - London-based biotechnology company, focused on developing medicines for hard-to-treat cancers - Announces the development of new small interfering ribonucleic acid sequences. Says sequences expand its portfolio of siRNA medicines, which it purchased through its acquisition of London-based cancer medications company Oncogeni Ltd in September. Adds it has completed a new patent filing to strengthen its siRNA patent pisition. Says the sequences are being developed alongside nano-particle delivery systems to target hard-to-treat, high mortality solid cancers. Results are expected in the fourth quarter of 2023.

Current stock price: 9.00 pence, up 11% on Monday

12-month change: up 7.4%

By Sabrina Penty, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Latest news about Roquefort Therapeutics plc

EARNINGS AND TRADING: Aura confident in Tiris; Cindrigo enters Germany	Apr. 26	AN
Earnings Flash (ROQ.L) ROQUEFORT THERAPEUTICS Reports FY23 Loss GBX-1.35	Apr. 26	MT
Roquefort Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 26	CI
Roquefort cancels fundraise after "unusual" stock movements	Apr. 05	AN
Roquefort Therapeutics Shelves Potential Placing Following Unusual Price Movements	Apr. 05	MT
Roquefort celebrates "significant milestones" in cancer research	Mar. 11	AN
Roquefort Therapeutics plc Provides an Update on the Development of the Midkine Midkine mRNA and STAT-6 siRNA programs	Mar. 11	CI
Roquefort hails further MK studies, licence talks continue	Feb. 06	AN
Roquefort Therapeutics plc Provides an Update on Its Pre-Clinical Drug Development Programs	Feb. 06	CI
Roquefort Therapeutics Announces Significant Mesodermal Killer Cell Milestone	Nov. 06	CI
EARNINGS: Biome loss widens; Amicorp focused on growth post-IPO	23-09-27	AN
Roquefort Therapeutics plc Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-27	CI
Roquefort files patent application for mRNA and RNA therapies	23-08-14	AN
Roquefort Therapeutics Files International Patent for Anti-cancer Therapeutics	23-08-14	MT
Roquefort Therapeutics plc Announces the Successful Filing of the International Phase PCT Patent for Its Proprietary Anti-Cancer mRNA and RNA Oligonucleotide Therapeutics	23-08-14	CI
Roquefort announces new sirNA sequences and patent filing	23-08-07	AN
Roquefort Therapeutics Completes Development of Four Novel Small Interfering RNA Sequences; Shares Up 5%	23-08-07	MT
Anpario trading in line, Likewise Group sales rise	23-06-29	AN
Plant Health Care announces GBP2.8 million fundraise	23-06-22	AN
Roquefort Therapeutics Expects Q4 Closing for In Vivo Studies for Anti-Cancer Program	23-06-22	MT
Roquefort Therapeutics celebrates cancer antibody trial results	23-06-19	AN
Roquefort Therapeutics' Bone Cancer Antibodies Lower Tumor Growth Rate in Efficacy Trial	23-06-19	MT
Roquefort says anti-cancer mRNA study shows positive results	23-06-13	AN
Roquefort Therapeutics Says mRNA Therapy Reduces Liver, Breast Cancer Growth	23-06-13	MT
Roquefort Therapeutics suspension on shares lifted	23-06-07	AN

Chart Roquefort Therapeutics plc

Duration

Period

More charts

Company Profile

Roquefort Therapeutics PLC is a biotechnology company. The Company is focused on developing pre-clinical medicines focused on treating hard-to-treat cancers. The Companyâs portfolio consists of five fully funded, patent-protected pre-clinical anti-cancer medicines. Its portfolio of medicines includes Midkine antibodies with in vivo efficacy and toxicology studies; Midkine oligonucleotide therapeutics with anti-cancer gene editing action; Midkine mRNA therapeutics targeting solid tumors; STAT-6 siRNA therapeutics targeting solid tumors with in vivo efficacy, and MK cell therapy with direct and NK-mediated anti-cancer action. The Company operates through its subsidiaries Lyramid Pty Ltd (Lyramid) and Oncogeni Ltd. Lyramid is engaged in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression). Oncogeni Ltd has developed two families of cell and RNA oncology medicines.

Sector

Investment Management & Fund Operators

Calendar

2024-10-24 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Investment Management & Fund Operators

	1st Jan change	Capi.
ROQUEFORT THERAPEUTICS PLC	-37.38%	7.32M
BLACKROCK, INC.	-6.00%	113B
APOLLO GLOBAL MANAGEMENT, INC.	+20.42%	63.85B
BROOKFIELD CORPORATION	+5.51%	61.9B
BANK OF NEW YORK MELLON CORPORATION (THE)	+10.82%	42.86B
AMERIPRISE FINANCIAL, INC.	+9.99%	40.84B
3I GROUP PLC	+18.88%	34.58B
T. ROWE PRICE GROUP INC.	+5.51%	25.46B
STATE STREET CORPORATION	-4.69%	22.13B
PRINCIPAL FINANCIAL GROUP, INC.	+2.21%	18.61B

Other Investment Management & Fund Operators